Get started
PARAMOUNT Stock Chart Fibonacci Analysis 042725Trading Idea 1) Find a FIBO slingshot 2) Check FIBO 61.80% level 3) Entry Point > 11.4/61.80% Chart time frame: C A) 15 min(1W-3M) B) 1 hr(3M-6M) C) 4 hr(6M-1year) D) 1 day(1-3years) Stock progress: D A) Keep rising over 61.80% resistance B) 61.80% resistance C) 61.80% support D) Hit the bottom E) Hit the top Stocks rise as they rise from support and fall from resistance. Our goal is to find a low support point and enter. It can be referred to as buying at the pullback point. The pullback point can be found with a Fibonacci extension of 61.80%. This is a step to find entry level. 1) Find a triangle (Fibonacci Speed Fan Line) that connects the high (resistance) and low (support) points of the stock in progress, where it is continuously expressed as a Slingshot, 2) and create a Fibonacci extension level for the first rising wave from the start point of slingshot pattern. When the current price goes over 61.80% level , that can be a good entry point, especially if the SMA 100 and 200 curves are gathered together at 61.80%, it is a very good entry point. As a great help, tradingview provides these Fibonacci speed fan lines and extension levels with ease. So if you use the Fibonacci fan line, the extension level, and the SMA 100/200 curve well, you can find an entry point for the stock market. At least you have to enter at this low point to avoid trading failure, and if you are skilled at entering this low point, with fibonacci6180 technique, your reading skill to chart will be greatly improved. If you want to do day trading, please set the time frame to 5 minutes or 15 minutes, and you will see many of the low point of rising stocks. If want to prefer long term range trading, you can set the time frame to 1 hr or 1 day.
NASDAQ:PARA
by fibonacci6180
TSLA bottom on Weekly chartI am calling a temporary bottom on TSLA stock due to Ichimoku cloud support on the Weekly chart. Ignore the bad news and all the other things going on. Price is everything. Stop losses should be placed below the cloud support. If It keeps going down and I end up being wrong SO BE IT. If it goes up from here then you can thank me later by buying me a coffee with your profits. But no Starbucks coffee please. I don't consider that coffee, more like road tar. Carry on recruits.
NASDAQ:TSLALong
by Metal-Rules_Rap-Sucks
HIMS: how I charted this + bullish/bearish/neutral scenarios! Bullish A break and hold above the 20EMA would shift momentum back to the upside. Initial resistance would be around 30, where previous price congestion sits. If buyers can push through, next target would be around 35–36, near the declining 50SMA. There is a short-term intraday trendline forming on the hourly chart that could act as a support guide if the stock starts climbing. Bearish A rejection from the downtrend line or failure to hold above the 20EMA could lead to a move lower. Breaking below the 24–25 support area would be a key bearish trigger. If that level fails, the next major downside target would be near 19.5. Neutral Continued sideways chop around the moving averages.
NYSE:HIMSLong
by emanuelaelias
Quantum's Walmart (WMT) Trading Guide 4/28/25WMT’s weekly outlook balances its defensive resilience against macroeconomic headwinds, with a comprehensive synthesis of technical, market, and strategic factors guiding its trajectory for weekly options contracts. The FAME framework underscores WMT’s long-term bullish potential, driven by robust fundamentals (+5% revenue, $0.58 EPS, 21% e-commerce growth) and adaptability (AI, Walmart+), positioning it as a resilient player in a risk-off regime. However, elevated yields (10-year 4.255%, 20-year 4.738%, 30-year 4.721%) and a stable DXY at 99.58 amplify tariff pressures and margin concerns, capping upside and reinforcing a cautious stance. A tactical long bias is favored for weekly contracts, targeting a bounce from $94.36 to $96.47–$98.50, with a short stance viable below $88.50 if support fails. Technical implications highlight bullish momentum on daily (RSI ~40, Stochastic ~28) and weekly (RSI ~44, Stochastic ~32) timeframes, with oversold conditions signaling a rebound potential for weekly contracts if $94.36 holds. Monthly neutral momentum (RSI ~50) suggests consolidation, requiring a breakout above $96.47 to confirm bullish strength. This supports a short-term bounce but advises monitoring for sustained moves. Market influence implications reflect a risk-off environment, with high yields and a stable DXY increasing import costs, particularly amid tariff uncertainty from WMT’s upcoming Trump meeting. The VIX at 24.84 amplifies volatility, favoring WMT’s defensive appeal but heightening risks. WMT’s Q3 FY25 strength and e-commerce growth provide stability, supporting resilience near $94.36. OFD summary and implications reveal bearish pressure from Vanna (-$0.04), Charm (-$0.02), and DEX (-$0.06), driven by put-heavy flow and hedging demand tied to tariff fears. However, GEX (+$0.08) at the $95 strike pins price, stabilizing volatility and supporting a neutral-to-bullish bounce for weekly contracts if $94.36 holds, aligning with oversold technicals. Edge insights bolster the case for a bounce, with institutional buying at $94–$95 signaling accumulation, defensive retail sector strength outperforming cyclicals, and low short interest (1.4%) offering squeeze potential above $96.47. These factors enhance confidence in a tactical long bias for weekly contracts, provided support holds. Strategic outlook implications emphasize consolidation near $95.09, with $94.36 as a critical pivot. A break below risks $88.50, driven by tariff fears and bearish options flow, while a move above $96.47 targets $98.50, fueled by oversold signals and institutional support. The VIX at 24.84 and put-heavy options flow underscore volatility, but WMT’s defensive positioning mitigates downside, favoring a bounce in a risk-off regime. In summary, WMT’s weekly outlook hinges on defending $94.36, with oversold technicals, GEX pinning, and institutional buying supporting a bounce to $96.47–$98.50 for weekly contracts. Tariff risks, high yields, and DXY stability maintain a risk-off backdrop, capping upside and requiring vigilance for a break below support, which could shift bias to bearish. This balanced approach leverages WMT’s defensive strengths while navigating weekly volatility, aligning with Buffett’s preference for resilient businesses with tactical opportunities.
NYSE:WMT
by QuantumEdgeAnalytics
SRPT LongSarepta Therapeutics Focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases investorrelations.sarepta.com Major leader in treatment - Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) - Explore perespective produts in Gene therapy and editing Fundamentals: - Growing Revenue and EPS - Trading at historical low PE - Far below market consensus $148 Technicals - Near low 200VWAP extension 30% discount
NASDAQ:SRPTLong
by fondOrange28771
Marker Therapeuticss a high-risk, high-reward investmeMarker Therapeutics (NASDAQ: MRKR) is a biotech company focused on multi-antigen T cell (MAR-T) therapies targeting hematological malignancies and solid tumors. The company recently published its FY2024 results, highlighting promising clinical progress but also significant financial challenges. As of the end of 2024, Marker reported $19.2 million in cash, with an annual operational burn rate of approximately $10.9 million. This cash position suggests a financial runway extending through the first quarter of 2026, assuming no additional financing. However, the company issued a "going concern warning" in its financial statements, flagging the risk of cash depletion within 12–15 months​. On the clinical side, preliminary data from the APOLLO trial for its lead candidate MT-601 in patients with relapsed/refractory lymphoma post-CAR-T therapy are encouraging, with an objective response rate (ORR) of 78% and a complete response (CR) rate of 44%. Meanwhile, the pancreatic cancer program for MT-601, backed by over $11.5 million in non-dilutive NIH and CPRIT grants, is set to enter clinical development in the second half of 2025. An additional milestone was the approval of "neldaleucel" as the official generic name for MT-601, marking regulatory progress. Nevertheless, Marker faces substantial structural risks. These include its heavy reliance on the success of MT-601, the urgent need for new funding within the next year, intense competition in the cellular therapy field, and complete reliance on third-party manufacturers after selling its own production facilities. From a valuation perspective, two scenarios can be considered. In a conservative scenario, assuming only partial success in the lymphoma program and dilutive fundraising, the estimated enterprise value would be around $24–26 million, corresponding to a theoretical share price of approximately $2.40–2.60. In an optimistic scenario, assuming full clinical success across both lymphoma and pancreatic programs and effective fundraising, the market valuation could rise to $75–95 million, implying a theoretical share price of about $8.80. However, adjusting for early-stage biotech risk (estimated success probability of 10–15%), the realistic fair value ranges between $0.90 and $1.30 per share​. In conclusion, Marker Therapeutics represents a high-risk, high-reward investment opportunity, suitable only for highly specialized biotech investors. The coming months will be critical, with particular focus on updated APOLLO trial data and the company's ability to secure additional funding or strategic partnerships.
NASDAQ:MRKR
by andreapriolo10
LGVN Bullish opportunity Longeveron Inc. (LGVN) offers a strong bullish opportunity as it nears a potential breakout from its prevailing downtrend. The stock has been consolidating with increasing volume and tightening price ranges, indicating accumulating buyer interest. A decisive break above the critical resistance level of $1.92, coinciding with the downtrend's upper trendline, could trigger a bullish reversal, propelling LGVN toward an initial target of $2.25, with further upside potential to $2.60. Traders should watch for strong volume confirmation and stay mindful of broader market conditions to manage risks effectively. Not advise for buying or selling, just I like what I do :)
NASDAQ:LGVNLong
by NEVERMINDS1
$EBAY $80 EOYA non factor amongst tariff rhetoric. I think the idea of US consumers (even internationally) buying and reselling has never been higher. I think a lot of consumers will start to look for used goods more than ever. I'm eyeing $70 calls for earnings this upcoming week (first week of May 2025) and if it has any pull back I will load the boat for $80 call leaps. I like the structure it's held at this $55-$65 range. I expect new highs on this name maybe earnings can give it a jolt. All the lines you see are 20, 50, 200 SMA and EMA. I could be wrong on earnings as this name tends to dip from earnings even posting beats but that's the gamble of earnings but LONG TERM this name is a good buy. Charts are Monthly and Daily. WSL.
NASDAQ:EBAYLong
by wallstreetloser001
IQiyi (IQ) - updating the Chart and story-trading during crisisNASDAQ:IQ some notes on the iqiyi chart. 1: fundamentals: the stock is expected to earn 20 cents this year and eventually grow to 50 cents per share eps, earnings power and earnings growth is very attractive at current prices. 2:Technicals: 2.00 level is significant for may and june options cycle. could we be in a major wedge at the 3 to 1.50 levels, marking a coiling up area. we took out the all time low of oct 2022 and make a new low around 1.50. , could this become a major accumulation zone during the trump/china tarriff crisis? 3.Sentiment: chinese stocks are very hated and under owned, there are many chinese stocks trading at or below tangible book value, news is very dark seeming for trade in china, with many chinese manufacturers shutting down due to lack of usa product demand with tarriff uncertainty. Bullish I love moments like this. they are not easy to trade and invest in. But they are real time history happening before our eyes. Sand through your hands. Remember these times.
NASDAQ:IQLong
by ValuePig
1